Published in Infect Immun on November 01, 1990
"Black holes" and bacterial pathogenicity: a large genomic deletion that enhances the virulence of Shigella spp. and enteroinvasive Escherichia coli. Proc Natl Acad Sci U S A (1998) 5.02
Genetic basis of virulence in Shigella species. Microbiol Rev (1991) 4.94
Evolutionary relationships among pathogenic and nonpathogenic Escherichia coli strains inferred from multilocus enzyme electrophoresis and mdh sequence studies. Infect Immun (1997) 3.97
Enteric bacterial toxins: mechanisms of action and linkage to intestinal secretion. Microbiol Rev (1996) 3.46
Identification and cloning of a novel plasmid-encoded enterotoxin of enteroinvasive Escherichia coli and Shigella strains. Infect Immun (1995) 2.45
Shigella enterotoxin 1: an enterotoxin of Shigella flexneri 2a active in rabbit small intestine in vivo and in vitro. J Clin Invest (1995) 2.41
Enterotoxigenicity of Vibrio parahaemolyticus with and without genes encoding thermostable direct hemolysin. Infect Immun (1992) 2.35
Safety, immunogenicity, and efficacy in monkeys and humans of invasive Escherichia coli K-12 hybrid vaccine candidates expressing Shigella flexneri 2a somatic antigen. Infect Immun (1992) 1.39
Effect of shigella enterotoxin 1 (ShET1) on rabbit intestine in vitro and in vivo. Gut (1997) 1.34
Mycoplasma pulmonis inhibits electrogenic ion transport across murine tracheal epithelial cell monolayers. Infect Immun (1998) 0.83
Chromosomal and plasmid-encoded factors of Shigella flexneri induce secretogenic activity ex vivo. PLoS One (2012) 0.80
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem (1976) 903.81
Nucleotide sequence of the rightward operator of phage lambda. Proc Natl Acad Sci U S A (1975) 56.75
Adenosine 3',5'-phosphate in biological materials. I. Purification and properties of cyclic 3',5'-nucleotide phosphodiesterase and use of this enzyme to characterize adenosine 3',5'-phosphate in human urine. J Biol Chem (1962) 12.79
Escherichia coli that cause diarrhea: enterotoxigenic, enteropathogenic, enteroinvasive, enterohemorrhagic, and enteroadherent. J Infect Dis (1987) 12.26
Experimental shigella keratoconjunctivitis; a preliminary report. Acta Microbiol Acad Sci Hung (1955) 11.91
Pathogenesis of Escherichia coli diarrhea. N Engl J Med (1971) 10.36
Escherichia coli strains that cause diarrhoea but do not produce heat-labile or heat-stable enterotoxins and are non-invasive. Lancet (1978) 10.29
Production of Shigella dysenteriae type 1-like cytotoxin by Escherichia coli. J Infect Dis (1982) 8.05
Quantitative microtiter cytotoxicity assay for Shigella toxin. J Clin Microbiol (1980) 7.68
An improved colony hybridization method with significantly increased sensitivity for detection of single genes. Plasmid (1983) 6.93
DNA probes for Shiga-like toxins I and II and for toxin-converting bacteriophages. J Clin Microbiol (1988) 5.04
Characterization of virulence plasmids and plasmid-associated outer membrane proteins in Shigella flexneri, Shigella sonnei, and Escherichia coli. Infect Immun (1983) 4.82
Identification and antigenic characterization of virulence-associated, plasmid-coded proteins of Shigella spp. and enteroinvasive Escherichia coli. Infect Immun (1985) 3.78
Characterization of invasion plasmid antigen genes (ipaBCD) from Shigella flexneri. Proc Natl Acad Sci U S A (1988) 3.65
Production of Shiga-like toxin by Escherichia coli. J Infect Dis (1986) 3.53
Use of DNA probes and HEp-2 cell adherence assay to detect diarrheagenic Escherichia coli. J Infect Dis (1988) 3.19
High-molecular-weight plasmid correlates with Escherichia coli enteroinvasiveness. Infect Immun (1982) 2.95
The role of Shigella spp., enteroinvasive Escherichia coli, and other enteropathogens as causes of childhood dysentery in Thailand. J Infect Dis (1986) 2.06
Comparison of DNA probes and the Sereny test for identification of invasive Shigella and Escherichia coli strains. J Clin Microbiol (1986) 1.96
Shiga-like toxin converting phage of enterohemorrhagic Escherichia coli strain 933. Microb Pathog (1989) 1.60
Clinical and microbiologic features of Shigella and enteroinvasive Escherichia coli infections detected by DNA hybridization. J Clin Microbiol (1988) 1.57
The relation between production of cytotoxin and clinical features in shigellosis. J Infect Dis (1986) 1.54
Invasive enteropathic Escherichia coli dysentery. An outbreak in 28 adults. Ann Intern Med (1973) 1.47
Outbreak of invasive Escherichia coli gastroenteritis on a cruise ship. Am J Trop Med Hyg (1984) 1.44
Recombinant DNA risk assessment studies in humans: efficacy of poorly mobilizable plasmids in biologic containment. J Infect Dis (1983) 1.40
Genetic relatedness of the basic replicon of the virulence plasmid in shigellae and enteroinvasive Escherichia coli. Microb Pathog (1988) 1.19
Effects of berberine on basal and secretagogue-modified ion transport in the rabbit ileum in vitro. J Pediatr Gastroenterol Nutr (1988) 1.14
DNA probes for identification of enteroinvasive Escherichia coli. J Clin Microbiol (1987) 1.01
Characterization of virulence marker antigen of Shigella spp. and enteroinvasive Escherichia coli. J Clin Microbiol (1989) 1.01
Lack of Shiga-like cytotoxin production by enteroinvasive Escherichia coli. J Clin Microbiol (1988) 0.86
Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med (2001) 9.99
Diabetic clinics today and tomorrow: mini-clinics in general practice. Br Med J (1973) 7.41
Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem (2001) 7.03
Production of collagenase and prostaglandins by isolated adherent rheumatoid synovial cells. Proc Natl Acad Sci U S A (1976) 5.40
TBX1 is responsible for cardiovascular defects in velo-cardio-facial/DiGeorge syndrome. Cell (2001) 4.60
A bacteriophage encoding a pathogenicity island, a type-IV pilus and a phage receptor in cholera bacteria. Nature (1999) 3.89
An interleukin 1 like factor stimulates bone resorption in vitro. Nature (1984) 3.71
Vibrio cholerae produces a second enterotoxin, which affects intestinal tight junctions. Proc Natl Acad Sci U S A (1991) 3.43
Aggregative adherence fimbriae I of enteroaggregative Escherichia coli mediate adherence to HEp-2 cells and hemagglutination of human erythrocytes. Infect Immun (1992) 3.30
Optic flow is used to control human walking. Nat Neurosci (2001) 3.12
Field trial of oral cholera vaccines in Bangladesh. Lancet (1986) 2.85
Isogenic P-fimbrial deletion mutants of pyelonephritogenic Escherichia coli: the role of alpha Gal(1-4) beta Gal binding in virulence of a wild-type strain. Mol Microbiol (1993) 2.80
Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci U S A (1999) 2.66
Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial. J Infect Dis (1988) 2.57
Identification and cloning of a novel plasmid-encoded enterotoxin of enteroinvasive Escherichia coli and Shigella strains. Infect Immun (1995) 2.45
A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med (1998) 2.42
Cloning of the cytotoxin-hemolysin gene of Vibrio vulnificus. Infect Immun (1985) 2.42
Shigella enterotoxin 1: an enterotoxin of Shigella flexneri 2a active in rabbit small intestine in vivo and in vitro. J Clin Invest (1995) 2.41
Enterotoxigenicity of Vibrio parahaemolyticus with and without genes encoding thermostable direct hemolysin. Infect Immun (1992) 2.35
Experimental non-O group 1 Vibrio cholerae gastroenteritis in humans. J Clin Invest (1990) 2.33
Virulence and phenotypic characterization of Yersinia enterocolitica isolated from humans in the United States. J Clin Microbiol (1983) 2.32
Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science (1969) 2.30
Relative contributions of distinct MHC class I-dependent cell populations in protection to tuberculosis infection in mice. Proc Natl Acad Sci U S A (2000) 2.20
Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science (1969) 2.20
Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol (1997) 2.14
New virulence-associated plasmid in Yersinia enterocolitica. J Clin Microbiol (1982) 2.03
Stimulation by human interleukin 1 of cartilage breakdown and production of collagenase and proteoglycanase by human chondrocytes but not by human osteoblasts in vitro. Biochim Biophys Acta (1984) 2.00
Construction of an MR/P fimbrial mutant of Proteus mirabilis: role in virulence in a mouse model of ascending urinary tract infection. Infect Immun (1994) 1.91
Purification, morphology, and genetics of a new fimbrial putative colonization factor of enterotoxigenic Escherichia coli O159:H4. Infect Immun (1987) 1.86
Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dichloromethylene diphosphonate (Cl 2 MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats. Calcif Tissue Res (1973) 1.85
Contribution of Proteus mirabilis urease to persistence, urolithiasis, and acute pyelonephritis in a mouse model of ascending urinary tract infection. Infect Immun (1993) 1.82
Purification and determination of the structure of capsular polysaccharide of Vibrio vulnificus M06-24. J Bacteriol (1992) 1.81
Effects of 1,25-dihydroxycholecalciferol on calcium absorption, muscle weakness, and bone disease in chronic renal failure. Lancet (1974) 1.80
Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest (1989) 1.79
Inorganic pyrophosphate in plasma, urine, and synovial fluid of patients with pyrophosphate arthropathy (chondrocalcinosis or pseudogout). Lancet (1970) 1.77
Field trial of oral cholera vaccines in Bangladesh: results of one year of follow-up. J Infect Dis (1988) 1.76
Clinical and immunologic characteristics of Vibrio cholerae O139 Bengal infection in North American volunteers. J Infect Dis (1995) 1.75
Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res (1997) 1.72
Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease. Lancet (1980) 1.68
Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis. Nature (1966) 1.68
Seroprevalence of Helicobacter pylori in Seventh-Day Adventists and other groups in Maryland. Lack of association with diet. Arch Intern Med (1990) 1.68
Pyrophosphate and diphosphonates in calcium metabolism and their possible role in renal failure. Arch Intern Med (1969) 1.64
Rate of reversal of hypercalcaemia and hypercalciuria induced by vitamin D and its 1alpha-hydroxylated derivatives. Br Med J (1977) 1.62
Seroprevalence of Helicobacter pylori in Chile: vegetables may serve as one route of transmission. J Infect Dis (1993) 1.59
Role of T-lymphocytes in the pathogenesis of herpetic stromal keratitis. Invest Ophthalmol Vis Sci (1984) 1.58
Interleukin-6 does not stimulate bone resorption in neonatal mouse calvariae. J Bone Miner Res (1991) 1.57
Characterization of enterotoxigenic Escherichia coli isolated from U.S. troops deployed to the Middle East. J Clin Microbiol (1993) 1.57
Biochemistry and immunology of infectious bursal disease virus. J Gen Virol (1988) 1.56
Inorganic pyrophosphate in plasma in normal persons and in patients with hypophosphatasia, osteogenesis imperfecta, and other disorders of bone. J Clin Invest (1971) 1.55
Diphosphonates. Experimental and clinical aspects. J Bone Joint Surg Br (1973) 1.54
Individual somatic H1 subtypes are dispensable for mouse development even in mice lacking the H1(0) replacement subtype. Mol Cell Biol (2001) 1.52
1,25-dihydroxycholecalciferol and 1alpha-hydroxycholecalciferol in hypoparathyroidism. Lancet (1974) 1.49
Is 24,25-dihydroxycholecalciferol a calcium-regulating hormone in man? Br Med J (1978) 1.49
Diphosphonates in Paget's disease. Lancet (1974) 1.47
Spinal cord dysfunction in Paget's disease of bone. Has medical treatment a vascular basis? J Bone Joint Surg Br (1981) 1.46
Toxin production by Vibrio mimicus strains isolated from human and environmental sources in Bangladesh. J Clin Microbiol (1987) 1.46
Human synovium releases a factor which stimulates chondrocyte production of PGE and plasminogen activator. Nature (1980) 1.45
Inhibition by pyrophosphate and polyphosphate of aortic calcification induced by vitamin D3 in rats. Clin Sci (1968) 1.43
Construction and characterization of attenuated delta aroA delta virG Shigella flexneri 2a strain CVD 1203, a prototype live oral vaccine. Infect Immun (1994) 1.43
Recovery from lethal herpes simplex virus type 1 infection is mediated by cytotoxic T lymphocytes. Infect Immun (1983) 1.43
Production of osteocalcin by human bone cells in vitro. Effects of 1,25(OH)2D3, 24,25(OH)2D3, parathyroid hormone, and glucocorticoids. Metab Bone Dis Relat Res (1984) 1.42
Intravenous clodronate in the treatment and retreatment of Paget's disease of bone. Lancet (1985) 1.42
Overview of bisphosphonates. Cancer (1997) 1.40
Paget's disease of bone. Experience with a diphosphonate (disodium etidronate) in treatment. Q J Med (1973) 1.40
Field trial of inactivated oral cholera vaccines in Bangladesh: results from 5 years of follow-up. Vaccine (1996) 1.39
The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res (1998) 1.39
Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. J Bone Miner Res (1998) 1.36
Early treatment with erythromycin of Campylobacter jejuni-associated dysentery in children. J Pediatr (1986) 1.36
The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised rats. Calcif Tissue Res (1970) 1.35
Phenotypic diversity of enterotoxigenic Escherichia coli strains from a community-based study of pediatric diarrhea in periurban Egypt. J Clin Microbiol (1999) 1.35
Milk immunoglobulin with specific activity against purified colonization factor antigens can protect against oral challenge with enterotoxigenic Escherichia coli. J Infect Dis (1998) 1.34
Yersinia enterocolitica isolated from two cohorts of young children in Santiago, Chile: incidence of and lack of correlation between illness and proposed virulence factors. J Clin Microbiol (1991) 1.34
Molecular mechanisms of action of bisphosphonates. Bone (1999) 1.33
Treatment of renal bone disease with 1 alpha-hydroxylated derivatives of vitamin D3. Clinical, biochemical, radiographic and histological responses. Q J Med (1979) 1.32
Biotype as determinant of natural immunising effect of cholera. Lancet (1991) 1.32
Comparison of Escherichia coli strains recovered from human cystitis and pyelonephritis infections in transurethrally challenged mice. Infect Immun (1998) 1.32
Space-time behavior of single and bimanual rhythmical movements: data and limit cycle model. J Exp Psychol Hum Percept Perform (1987) 1.32
DNA probe analysis of diarrhoeagenic Escherichia coli: detection of EAF-positive isolates of traditional enteropathogenic E. coli serotypes among Bangladeshi paediatric diarrhoea patients. Mol Cell Probes (1992) 1.32
Identification of Shigella flexneri subserotype 1c in rural Egypt. J Clin Microbiol (1999) 1.30
Stimulation of the proliferation of human bone cells in vitro by human monocyte products with interleukin-1 activity. J Clin Invest (1985) 1.30
The interrelationship between thromboxane biosynthesis, aggregation and 5-hydroxytryptamine secretion in human platelets in vitro. Thromb Haemost (1980) 1.30
Myositis ossificans progressiva. Clinical features of eight patients and their response to treatment. J Bone Joint Surg Br (1976) 1.30
Localization of the murine reduced folate carrier as assessed by immunohistochemical analysis. Biochim Biophys Acta (2001) 1.29
Hypophosphatasia and the extracellular metabolism of inorganic pyrophosphate: clinical and laboratory aspects. Crit Rev Clin Lab Sci (1991) 1.28
Estrogen inhibits release of tumor necrosis factor from peripheral blood mononuclear cells in postmenopausal women. J Bone Miner Res (1990) 1.25
Diphosphonates and Page's disease of bone. Lancet (1971) 1.24
Cell-mediated immunity to herpes simplex virus: recognition of type-specific and type-common surface antigens by cytotoxic T cell populations. Infect Immun (1981) 1.24
Strategy for cross-protection among Shigella flexneri serotypes. Infect Immun (1999) 1.23
Epidemiology of enterotoxigenic Escherichia coli diarrhea in a pediatric cohort in a periurban area of lower Egypt. J Infect Dis (1999) 1.21
Epidemiology and etiology of diarrhea in colony-born Macaca nemestrina. Lab Anim Sci (1987) 1.20
Development of an in vitro model for study of non-O1 Vibrio cholerae virulence using Caco-2 cells. Infect Immun (1990) 1.20
Diagnostic value of plasmid analyses and assays for virulence in Yersinia enterocolitica. Diagn Microbiol Infect Dis (1984) 1.19
Purification and analysis of colonization factor antigen I, coli surface antigen 1, and coli surface antigen 3 fimbriae from enterotoxigenic Escherichia coli. J Bacteriol (1989) 1.19
The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo. Eur J Clin Invest (1970) 1.18
Rescue of embryonic lethality in reduced folate carrier-deficient mice by maternal folic acid supplementation reveals early neonatal failure of hematopoietic organs. J Biol Chem (2001) 1.18
Evaluation of bone turnover in type I osteoporosis using biochemical markers specific for both bone formation and bone resorption. Osteoporos Int (1993) 1.18
Metabolism of inorganic pyrophosphate (PPi). Arthritis Rheum (1976) 1.17
In vitro activation of human chondrocytes and synoviocytes by a human interleukin-1-like factor. Arthritis Rheum (1984) 1.17
Pathogenesis of chondrocalcinosis and pseudogout. Metabolism of inorganic pyrophosphate and production of calcium pyrophosphate dihydrate crystals. Ann Rheum Dis (1983) 1.17